Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.59 |
| ▸ | FAP | Q12884 | 1/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.59 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511428 | 1.00 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL1695702 | 0.86 | DPP4 (0.46) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL21226746 | 0.77 | DPP4 (0.59) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL28054657 | 0.77 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL28054834 | 0.77 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL1798265 | 0.77 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL16307729 | 0.77 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL1798266 | 0.77 | DPP4 (0.62) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL30924754 | 0.75 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL6371844 | 0.75 | DPP4 (0.60) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-10584313-B2 | Method of producing a differentiated mammalian cell comprising culturing a single mammalian blastomere | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2020-03-10 | — | — | US | disclosed |
| US-10072243-B2 | Derivation of embryonic stem cells and embryo-derived cells | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170240857-A1 | DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS | ADVANCED CELL TECHNOLOGY, INC. | 2017-08-24 | — | — | US | disclosed |
| EP-3190178-A1 | HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS | Astellas Institute for Regenerative Medicine (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9617512-B2 | Derivation of embryonic stem cells and embryo-derived cells | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE (US) | 2017-04-11 | — | — | US | disclosed |
| EP-3133150-A2 | DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS | Astellas Institute for Regenerative Medicine (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2982744-A1 | HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS | Advanced Cell Technology, Inc. (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2029724-A2 | DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS | Advanced Cell Technology, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008103462-A2 | HIGHLY EFFICIENT METHODS FOR REPROGRAMMING DIFFERENTIATED CELLS AND FOR GENERATING ANIMALS AND EMBRYONIC STEM CELLS FROM REPROGRAMMED CELLS | ADVANCED CELL TECHNOLOGY, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| US-20080057041-A1 | Derivation of embryonic stem cells and embryo-derived cells | ADVANCED CELL TECHNOLOGY, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007130664-A2 | DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-5847155-A | Aromatic pyrrolidine amide prolyl endopeptidase inhibitors | PFIZER INC (US) | 1998-12-08 | — | — | US | disclosed |
| US-5451571-A | Administering Z-proprolinal | THE CLEVELAND CLINIC FOUNDATION (US) | 1995-09-19 | — | — | US | disclosed |
| EP-0536163-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1993-04-14 | — | — | EP | disclosed |
| WO-1991018891-A1 | AROMATIC PYRROLIDINE AND THIAZOLIDINE AMIDES | PFIZER INC. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218577-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORS FOR THE TREATMENT OF NEURODEVELOPMENTAL DISORDERS | HSP90AB1, HSP90AA1, HSF1 | DPP4 4568/4885DPP8 4264/4885DPP9 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.